



Certificate No: IQ-24112602/A

MAHAMAYA LIFESCIENCES LIMITED

(Formerly Known as Mahamaya Lifesciences Pvt. Ltd.)

369, 370, 370A and 370B, 3rd Floor, Tower B-1,
Spaze ITech Park, Sector-49, Sohna Road,
Gurugram - 122018, Haryana, India
Tel. : +91-124-4301988 / 4101430 / 4371988
E-mail : info@mahamayalifesciences.com
Web : www.mahamayalifesciences.com

CIN : U24233DL2002PLC115261

Date: November 10, 2025

To
The General Manager
Dept. of Corporate Services
Bombay Stock Exchange Limited
PJ Towers,
Mumbai Samachar Marg, Mumbai - 400 001

Dear Sir,

Sub: Public Offer of upto 61,78,800 Equity Shares comprising of Fresh Issue of 56,38,800 Equity Shares and Offer for Sale of 5,40,000 Equity Shares having Face Value of Rs. 10.00 each by Mahamaya Lifesciences Limited ("Company")

The Board of Directors of the Company and Selling Shareholders at their respective meetings held on November 10, 2025, in consultation with the Book Running Lead Manager to the Offer, has finalized allocation of 17,52,000 Equity Shares, to Anchor Investors at Anchor Investor allocation price of Rs. 114/- per Equity Share (including share premium of Rs.104/- per Equity Share) in the following manner:

Sr. No.	Name of the Anchor Investor	No. of Equity Shares allocated	% of Anchor Investor Portion	Bid price (Rs. per Equity Share)
1	ABUNDANTIA CAPITAL VCC- ABUNDANTIA CAPITAL III	2,64,000	15.07%	114/-
2	ASCEND GLOBAL OPPORTUNITIES FUND	1,75,200	10.00%	114/-
3	EBISU GLOBAL OPPORTUNITIES FUND LIMITED	4,34,400	24.79%	114/-
4	VIKASA INDIA EIF I FUND - INCUBE GLOBAL OPPORTUNITIES	2,64,000	15.07%	114/-
5	AARTH AIF GROWTH FUND	1,32,000	7.53%	114/-
6	NAVBHARAT INVESTMENT TRUST- NAVBHARAT INVESTMENT OPPORTUNITIES FUND	1,75,200	10.00%	114/-
7	NAV CAPITAL VCC - NAV CAPITAL EMERGING STAR FUND	3,07,200	17.53%	114/-
TOTAL		17,52,000.00	100.00%	

No Mutual Fund have applied through any scheme for the Anchor Investor Portion.

As per the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations, 2018, as amended, in case the Offer Price discovered through book building process is higher than the Anchor Investor allocation price, Anchor investors will be required to pay the difference by the pay-in as specified in the revised CAN.



Please note that capitalized terms used and not defined herein shall have the respective meaning ascribed to them in the Red Herring Prospectus.

We request you to make the above information public by disclosing the same on your website.

Thanking You,
For **Mahamaya Lifesciences Limited**


Name: Krishnamurthy Ganesan
Designation: Managing Director
DIN: 00270539

